Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

BACKGROUND: Responses to bevacizumab in glioblastoma (GBM) are not durable. Plasma levels of basic fibroblast growth factor (bFGF) increase at the time of tumor progression. By targeting vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor, Src, and FGF recept...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Lee, Eudocia Q., Muzikansky, Alona, Duda, Dan G., Gaffey, Sarah, Dietrich, Jorg, Nayak, Lakshmi, Chukwueke, Ugonma N., Beroukhim, Rameen, Doherty, Lisa, Laub, Caroline Kane, LaFrankie, Debra, Fontana, Brittney, Stefanik, Jennifer, Ruland, Sandra, Caruso, Victoria, Bruno, Jennifer, Ligon, Keith, Reardon, David A., Wen, Patrick Y.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Clinical Cancer Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6792497/
https://ncbi.nlm.nih.gov/pubmed/31444999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2505
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares